Is neoadjuvant immunotherapy feasible for patients with dMMR/MSI−H locally advanced colorectal cancer? a retrospective study
Neoadjuvant immunotherapy appears to be a safe and effective treatment for patients with dMMR/MSI-H LACRC, offering a feasible and acceptable therapeutic regimen before surgery.
Authors
- Danjun Wang (ORCID: https://orcid.org/0000-0003-1038-4901)
- Renshen Xiang (ORCID: https://orcid.org/0009-0001-5756-1576)
- Zhexue Wang (ORCID: https://orcid.org/0009-0006-4020-216X)
- Zhenkai Luo
- Hang Zhao (ORCID: https://orcid.org/0000-0002-1069-569X)
Institutions
- Shanghai Medical College of Fudan University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- National Cancer Center (US)
- Shanghai Medical Information Center (CN)
- Fudan University Shanghai Cancer Center (CN)
- Zhejiang Cancer Hospital (CN)
- YangPu Geriatric Hospital (CN)
- Hangzhou Cancer Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-08-12
- DOI
- https://doi.org/10.3389/fimmu.2025.1645412
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05